AbbVie Inc.’s IL-23 inhibitor Skyrizi (risankizumab) delivered its first set of positive Phase III results in ulcerative colitis (UC) on 23 March from INSPIRE, a 12-week induction study, and the company plans to report data from Phase III COMMAND clinical trial, a 52-week maintenance study, during the first half of 2023. Positive results from both trials will position the product for regulatory filings later this year and a launch in UC – an increasingly crowded market, particularly for IL-23 inhibitors – in 2024.
Skyrizi already is approved in the US, EU and several other markets for Crohn’s disease, giving the product a foothold...